Opendata, web and dolomites

SENATOR TERMINATED

Staff Exchange for Novel applications in 19f magnetic resonance imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SENATOR project word cloud

Explore the words cloud of the SENATOR project. It provides you a very rough idea of what is the project "SENATOR" about.

cells    imaging    situations    invasive    animals    magnetic    biology    living    opened    absolutely    tissue    limit    quantitative    generation    released    surrounding    active    modality    inside    labelled    announcement    nanoparticles    door    whilst    smart    resonance    body    move    clinical    payload    repeated    functionalisation    spurred    agents    risk    gadolinium    healthcare    mri    safety    structures    deemed    therapeutic    area    deposits    tolerated    expansion    signatures    background    ligands    mounting    patients    visualised    historically    kidneys    found    tissues    contrast    incorporated    brain    2015    perfluorocarbon    until    materials    novelty    imaged    signal    impairment    resolution    fda    accumulate    multifunctional    biomaterial    migration    safe    basis    gbca    reagents    administered    insights    regarding    discrimination    advised    gbcas    diagnostic    cell    19f    renal    professionals    trafficking    bone    molecular    competing    generally    accumulated    preclinical    technique    individual   

Project "SENATOR" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 1˙541˙000 €
 EC max contribution 1˙541˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 234˙600.00
2    PERCUROS BV NL (LEIDEN) participant 202˙400.00
3    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 165˙600.00
4    UNIVERSITA DEGLI STUDI DI CAMERINO IT (CAMERINO) participant 161˙000.00
5    TECOBIOSCIENCES GMBH DE (LANDSHUT) participant 156˙400.00
6    UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II IT (NAPOLI) participant 156˙400.00
7    MEDRES-MEDICAL RESEARCH GMBH DE (KOLN) participant 147˙200.00
8    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 110˙400.00
9    GOOD BIOMARKER SCIENCES BV NL (SASSENHEIM) participant 82˙800.00
10    PROGREDUM GMBH DE (KAISERSLAUTERN) participant 82˙800.00
11    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 41˙400.00

Map

 Project objective

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique, which is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENATOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENATOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

EXPLOR (2020)

EXperimentation and simulation based PLatform for beyond 5G Optical-wireless network Research and development

Read More  

N-LIGHT (2020)

Novel Light Sources: Theory and Experiment

Read More  

GreenX4Drug (2019)

Green Enantioselective Halogenation for Drug Discovery and Manufacture

Read More  
lastchecktime (2020-10-27 20:56:57) correctly updated